Neurogene (NGNE) Institutional Ownership $15.33 -1.90 (-11.03%) (As of 11/20/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Neurogene (NASDAQ:NGNE)CurrentInstitutional OwnershipPercentage52.37%Number ofInstitutional Buyers(last 12 months)24TotalInstitutional Inflows(last 12 months)$97.82MNumber ofInstitutional Sellers(last 12 months)6TotalInstitutional Outflows(last 12 months)$11.66M Get NGNE Insider Trade Alerts Want to know when executives and insiders are buying or selling Neurogene stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data NGNE Institutional Buying and Selling by Quarter Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Neurogene Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/19/2024 Barclays PLC14,859$623K0.0%+319.4%0.114% 11/16/2024 Geode Capital Management LLC220,599$9.26M0.0%-0.7%1.698% 11/15/2024 Barclays PLC14,859$623K0.0%+319.4%0.114% 11/15/2024 Jane Street Group LLC7,717$324K0.0%N/A0.059% 11/15/2024 Wellington Management Group LLP18,290$767K0.0%N/A0.141% 11/15/2024 State Street Corp246,540$10.35M0.0%+17.5%1.898% Get the Latest News and Ratings for NGNE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter. 11/15/2024 RTW Investments LP1,135,256$47.64M0.7%+6.0%8.739% 11/15/2024 Redmile Group LLC964,347$40.46M2.4%-4.9%7.424% 11/15/2024 Janus Henderson Group PLC709,469$29.78M0.0%-15.0%5.462% 11/14/2024 Walleye Capital LLC44,500$1.87M0.0%-51.9%0.343% 11/14/2024 MetLife Investment Management LLC6,054$254K0.0%N/A0.047% 11/13/2024 BNP Paribas Financial Markets2,170$91K0.0%+192.8%0.017% 11/13/2024 FMR LLC731,801$30.71M0.0%+912.4%5.634% 11/12/2024 Charles Schwab Investment Management Inc.30,317$1.27M0.0%+2.5%0.233% 11/8/2024 Jennison Associates LLC78,650$3.30M0.0%N/A0.605% 11/7/2024 Quest Partners LLC1,279$54K0.0%-16.0%0.010% 10/3/2024 SG Americas Securities LLC3,576$150K0.0%N/A0.028% 8/16/2024 Driehaus Capital Management LLC102,187$3.72M0.0%+123.8%0.787% 8/14/2024 Marshall Wace LLP41,447$1.51M0.0%+37.2%0.319% 8/14/2024 Integral Health Asset Management LLC70,000$2.55M0.2%N/A0.539% 8/14/2024 Avoro Capital Advisors LLC22,029$802K0.0%N/A0.170% 8/9/2024 Renaissance Technologies LLC52,807$1.92M0.0%-10.0%0.407% 8/6/2024 Quest Partners LLC1,523$55K0.0%N/A0.012% 8/1/2024 Rhumbline Advisers13,489$491K0.0%N/A0.104% 7/26/2024 Bank of New York Mellon Corp30,428$1.11M0.0%N/A0.234% 5/16/2024 Janus Henderson Group PLC813,353$41.37M0.0%-3.4%6.266% 5/16/2024 Redmile Group LLC935,252$47.60M1.7%-1.2%7.205% 5/15/2024 Baker BROS. Advisors LP456,015$23.21M0.3%+0.6%3.513% 5/10/2024 Vanguard Group Inc.507,483$25.83M0.0%+906.5%3.943% 5/7/2024 SG Americas Securities LLC2,348$120K0.0%N/A0.018% 4/30/2024 Privium Fund Management UK Ltd5,860$274K0.1%N/A0.046% 2/15/2024 Great Point Partners LLC994,229$19.27M3.3%N/A42.326% 2/14/2024 Avidity Partners Management LP466,243$9.04M0.3%N/A19.840% 2/2/2024 BML Capital Management LLC24,666$478K0.4%N/A1.050% (Data available from 1/1/2016 forward) NGNE Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of NGNE shares? During the previous two years, 29 institutional investors and hedge funds held shares of Neurogene. The most heavily invested institutionals were RTW Investments LP ($47.64M), Redmile Group LLC ($40.46M), FMR LLC ($30.71M), Janus Henderson Group PLC ($29.78M), Vanguard Group Inc. ($25.83M), Baker BROS. Advisors LP ($23.21M), and Great Point Partners LLC ($19.27M).Learn more on NGNE's institutional investors. What percentage of Neurogene stock is owned by institutional investors? 52.37% of Neurogene stock is owned by institutional investors. Learn more on NGNE's institutional investor holdings. Which institutional investors have been buying Neurogene stock? Of the 24 institutional investors that purchased Neurogene stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Great Point Partners LLC ($994.23K), FMR LLC ($659.52K), Avidity Partners Management LP ($466.24K), Vanguard Group Inc. ($457.06K), Jennison Associates LLC ($78.65K), Integral Health Asset Management LLC ($70K), and RTW Investments LP ($64.69K). How much institutional buying is happening at Neurogene? Institutional investors have bought a total of 3,058,120 shares in the last 24 months. This purchase volume represents approximately $97.82M in transactions. Which Neurogene major shareholders have been selling company stock? The following institutional investors have sold Neurogene stock in the last 24 months: Janus Henderson Group PLC ($153.66K), Redmile Group LLC ($60.96K), Walleye Capital LLC ($48K), Renaissance Technologies LLC ($5.90K), Geode Capital Management LLC ($1.46K), and Quest Partners LLC ($244.00). How much institutional selling is happening at Neurogene? Institutional investors have sold a total of 270,225 shares in the last 24 months. This volume of shares sold represents approximately $11.66M in transactions. Related Companies ERAS Major Shareholders EOLS Major Shareholders PLRX Major Shareholders CRON Major Shareholders CGEM Major Shareholders PRTA Major Shareholders REPL Major Shareholders AUTL Major Shareholders CRGX Major Shareholders AVXL Major Shareholders This page (NASDAQ:NGNE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
